Open Access Case Report

Infliximab Redosing During Massive GI Bleeding Resulting from Severe Crohn’s Disease

Niharika Mallepally, Vijay Prabhakar, Sarah Sheibani and Jacques Van Dam*

Department of Gastroenterology, Keck School of Medicine of USC, USA

Corresponding Author

Received Date: October 27, 2022;  Published Date: November 18, 2022


In moderate-to-severe Crohn’s disease (CD), early introduction of biologics is indicated. However, a standard frequency induction regimen may be insufficient for disease activity control in patients with significant ongoing hematochezia. We present a previously healthy 21-year-old man who was found to have severe-fulminant CD with involvement of the esophagus, stomach, small intestine, and colon. Since his disease remained refractory despite an accelerated high-dose infliximab initiation regimen, an infliximab level was checked and returned undetectable. In patients with Crohn’s disease who present with large volume gastrointestinal hemorrhage, it is imperative to proactively assess infliximab levels and aggressively re-dose if needed.

Signup for Newsletter
Scroll to Top